Mode
Home
Conditions Medications Drug Pipeline Weekly Digests
Text Size
Log in / Sign up
Home › Medications › pimavanserin

pimavanserin

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Nuplazid (pimavanserin) for Parkinson's Disease Psychosis
Neurology FDA Approval
FDA Approves Nuplazid (pimavanserin) for Parkinson's Disease Psychosis FDA approves first drug for hallucinations in Parkinson's disease
FDA approved Nuplazid (pimavanserin) for hallucinations and delusions associated with Parkinson's disease psychosis. In a 6-week trial, Nupl…
The FDA approved Nuplazid (pimavanserin) to treat hallucinations and delusions in people with Parkinson's disease psychosis. It is the first…
FDA May 2, 2026
FDA Approves Nuplazid (pimavanserin) for Parkinson's Disease Psychosis
Neurology FDA Approval
FDA Approves Nuplazid (pimavanserin) for Parkinson's Disease Psychosis FDA approves first drug for hallucinations in Parkinson's disease
The FDA approved Nuplazid (pimavanserin) for hallucinations and delusions associated with Parkinson's disease psychosis. Approval was based …
The FDA approved Nuplazid (pimavanserin) to treat hallucinations and delusions in people with Parkinson's disease psychosis. It is the first…
FDA May 2, 2026